Osteoarthritis, Hip, Rheumatoid Arthritis
Conditions
Keywords
Single-cell RNA sequencing, Spatial transcriptomics, Osteoarthritis, Rheumatoid arthritis, Spatial proteomics
Brief summary
The purpose of this study is to cast light on the highly complex etiology and cellular landscape of hip osteoarthritis by utilising single-cell and spatial omics.
Detailed description
The specific objectives of this project are: 1. Using the latest single-cell RNA sequencing (scRNAseq) techniques the investigators aim to A) characterize what kind of cell populations are found in different synovial tissues and blood derived samples of OA patients, B) determine how the cell composition differs between arthritic and corresponding non-arthritic tissues, C) map the transcriptional and regulatory landscape of the cells mentioned in A and B focusing on the inflammatory responses, D) determine what are the key molecular pathways activated in OA. 2. To determine if some of the blood-derived immune cell populations or their products could be used as biomarkers for OA. 3. To map the whole transcriptome and proteome of OA and non-arthritic control tissue while keeping the morphological context with spatial omics technologies. 4. Further differentiation and identification of OA endotypes utilizing the single-cell and spatial omics data. The project includes a Rheumatoid sub-study where the main objective is to compare arthritic tissue and peripheral blood constituents between OA and rheumatoid arthritis patients to explore the differences in the disease mechanisms.
Interventions
PROCEDURETotal hip arthroplasty
Hip joint replacement surgery. Elective for RA and OA cases.
Sponsors
Turku University Hospital
Hospital District of Helsinki and Uusimaa
University of Turku
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
Yes
Inclusion criteria
for the main (OA) study: Cases: Adult patients with osteoarthritis in the hip joint and who are going through an elective total hip arthroplasty. Controls: Non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty. \---- Inclusion Criteria for the Rheumatoid sub-study: Adult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty. \----
Exclusion criteria
* The body mass index must be below 35 * Age \< 18 or \> 74 * The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome. For the Rheumatoid sub-study, the
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of cell populations between OA cases and controls | Starting during the first quarter of 2025, ending by the last quarter of 2026. | The investigators will determine how the cell composition differs between arthritic and corresponding non-arthritic tissues utilising single-cell RNA sequencing solutions. |
| Key molecular pathways of OA | Starting during the last quarter of 2025, ending by the last quarter of 2027. | The investigators will determine what are the key molecular pathways activated in OA. |
| Comparison of disease mechanisms between RA and OA | Starting during the last quarter of 2024, ending by the last quarter of 2028. | In the Rheumatoid sub-study the investigators will explore the differences in the disease mechanisms between OA and RA by comparing synovial tissues and peripheral blood sample constituents. |
| Characterization of cell populations in OA | Starting during the first quarter of 2025, ending by the last quarter of 2026. | Characterization of cell populations found in different synovial tissues and blood derived samples of OA patients utilising single-cell RNA sequencing solutions. |
| Cellular landscape in OA | Starting during the last quarter of 2024, ending by the last quarter of 2026. | The investigators will map the transcriptional, regulatory and protein landscape of OA at single-cell and tissue (spatial) level. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OA endotypes | Starting during the first half of 2025, ending by the second half of 2027. | The investigators aim to identify and further differentiate OA endotypes by utilizing the single-cell and spatial data. |
| Biomarkers for OA | Starting during the second half of 2026, ending by the last quarter of 2028. | The investigators will investigate if some of the blood-derived immune cell populations or their products could be used as biomarkers for OA. |
Countries
Finland
Contacts
Primary ContactLea Mikkola, PhD
Outcome results
None listed